

Global Myasthenia Gravis Treatment Market: Forecast and Trends

<https://marketpublishers.com/r/GF0CA1319AC3EN.html>

Date: November 2023

Pages: 120

Price: US\$ 5,500.00 (Single User License)

ID: GF0CA1319AC3EN

Abstracts

Report Scope:

This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.

Report Includes:

54 data tables and 47 additional tables

An overview and analysis of the global market for myasthenia gravis (MG) treatments

Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028

Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region

In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)

Analysis of the market growth opportunities through Porter's Five Forces and PESTLE analyses, taking into consideration the prevailing

micro%li%and macro environmental factors

An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies

Discussion of the factors driving the market, industry trends and new developments

Analysis of relevant patents

Identification of the leaders in the field of MG

Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Market Outlook
Report Highlights

CHAPTER 3 MARKET OVERVIEW

Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
North America
Europe
Asia-Pacific
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications

Surgery
Intravenous (IV) Therapy
Medications

CHAPTER 4 MARKET DYNAMICS

Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine
Market Opportunities
Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration
Market Restraints
Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies
Other Restraints

CHAPTER 5 MARKET BREAKDOWN BY REGION

Market Overview
North America
Europe
Asia-Pacific

CHAPTER 6 MARKET BREAKDOWN BY TYPE

Market Overview

Generalized Myasthenia Gravis

Transient Neonatal Myasthenia Gravis

Ocular Myasthenia Gravis

CHAPTER 7 MARKET BREAKDOWN BY TREATMENT MODALITY

Introduction

Medications

Surgery

Intravenous Therapy

CHAPTER 8 MARKET BREAKDOWN BY TYPE OF PRODUCT

Monoclonal Antibodies

Brands

Cholinesterase Inhibitors

Brand

Intravenous Immunoglobulins

Brands

Immunosuppressants

Brand

Corticosteroids

Brand

CHAPTER 9 ESG DEVELOPMENT

Introduction

Environment

Social

Governance

Case Study

AstraZeneca

Concluding Remarks from BCC Research

CHAPTER 10 EMERGING TECHNOLOGIES AND DEVELOPMENTS

Introduction

CHAPTER 11 COMPETITIVE INTELLIGENCE

Overview

Industry Scenario

Company Shares

CHAPTER 12 PATENT ANALYSIS

Patent Analysis by Manufacturer

CHAPTER 13 PIPELINE ANALYSIS

Clinical Trials

CHAPTER 14 M&A AND VENTURE FUNDING OUTLOOK

Introduction

CHAPTER 15 COMPANY PROFILES

ABBVIE

AMYASTHENIA GRAVISEN INC.

ASTELLAS PHARMA INC.

ASTRAZENECA

BAUSCH HEALTH COMPANIES INC.

BAYER AG

BIOGEN

BRISTOL-MYERS SQUIBB

CSL

DAIICHI SANKYO CO. LTD.

F. HOFFMANN-LA ROCHE AG

GILEAD SCIENCES INC.

GLAXOSMITHKLINE PLC.

MERCK & CO. INC.

NOVARTIS

PFIZER INC.

SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.

CHAPTER 16 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, Through 2028

Table 1 : Global Population, Aged 60+, 2010-2050

Table 2 : Factors Leading to the Increasing Incidence of Myasthenia Gravis Worldwide

Table 3 : Global Serological Testing for Myasthenia Gravis, by Type

Table 4 : Targeted Drug Therapies for the Treatment of Myasthenia Gravis

Table 5 : Diagnostic Challenges in the Treatment of Myasthenia Gravis

Table 6 : Risks of Emerging Therapies for Myasthenia Gravis, by Type

Table 7 : Global Market for the Treatment of Myasthenia Gravis, by Region, Through 2028

Table 8 : North American Market for the Treatment of Myasthenia Gravis, by Country, Through 2028

Table 9 : European Market for the Treatment of Myasthenia Gravis, by Country, Through 2028

Table 10 : Asia-Pacific Market for the Treatment of Myasthenia Gravis, by Country, Through 2028

Table 11 : Global Prevalence of Myasthenia Gravis, by Type

Table 12 : Global Market for the Treatment of Generalized Myasthenia Gravis, by Region, Through 2028

Table 13 : Global Market for the Treatment of Ocular Myasthenia Gravis, by Region, Through 2028

Table 14 : Global Market for the Treatment of Transient Neonatal Myasthenia Gravis, by Region, Through 2028

Table 15 : Global Market for Medications for the Treatment of Myasthenia Gravis, by Region, Through 2028

Table 16 : Global Market for Surgical Treatment of Myasthenia Gravis, by Region, Through 2028

Table 17 : Global Market for Intravenous Therapy for the Treatment of Myasthenia Gravis, by Region, Through 2028

Table 18 : Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028

Table 19 : Global Market for Monoclonal Antibodies for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028

Table 20 : Global Market for Cholinesterase Inhibitors for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028

Table 21 : Global Market for Intravenous Immunoglobulins for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028

Table 22 : Global Market for Immunosuppressants for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028

Table 23 : Global Market for Corticosteroids for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028

Table 24 : ESG Framework for the Global Pharmaceutical Industry

Table 25 : Social Framework of the Global Pharmaceutical Industry

Table 26 : Top Pharma Companies: ESG Ratings

Table 27 : AstraZeneca's Contribution to Sustainable Development Goals

Table 28 : AstraZeneca's Material Focus Areas

Table 29 : New Technologies for Myasthenia Gravis Treatments

Table 30 : New Pharmaceuticals for the Treatment of Myasthenia Gravis

Table 31 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022

Table 32 : Global Product Shares of Myasthenia Gravis Treatments, by Brand, 2022

Table 33 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022

Table 34 : Key Financials of Pharma Companies Offering Myasthenia Gravis Treatment Products, 2022

Table 35 : Patents on Myasthenia Gravis Treatments, 2018-Present

Table 36 : Selected Manufacturer Patents on Myasthenia Gravis Drugs, 2018-Present

Table 37 : Patents on Eculizumab, 2018-Present

Table 38 : Selected Manufacturer Patents on Eculizumab, 2018-Present

Table 39 : Patents on Efgartigimod alfa, 2018-Present

Table 40 : Selected Manufacturer Patents on Efgartigimod alfa, 2018-Present

Table 41 : Patents on Rituximab, 2018-Present

Table 42 : Selected Manufacturer Patents on Rituximab, 2018-Present

Table 43 : Patents on Pyridostigmine, 2018-Present

Table 44 : Selected Manufacturer Patents on Pyridostigmine, 2018-Present

Table 45 : Patents on Privigen, 2018-Present

Table 46 : Selected Manufacturer Patents on Privigen, 2018-Present

Table 47 : Clinical Trials on Myasthenia Gravis, as of 2023

Table 48 : Mergers and Acquisitions, 2019-2021

Table 49 : AbbVie: Product Information

Table 50 : AbbVie: Financial Overview, 2020-2022

Table 51 : AbbVie: Key Developments, 2021-2023

Table 52 : Amgen: Revenue, 2020-2022

Table 53 : Amgen: Key Developments, 2021 and 2022

Table 54 : Astellas Pharma: Revenue, 2020-2022

Table 55 : Astellas Pharma: Key Developments, 2018-2022

Table 56 : AstraZeneca: Product Information
Table 57 : AstraZeneca: Revenue, 2020-2022
Table 58 : AstraZeneca: Key Developments, 2022 and 2023
Table 59 : Bausch Health: Product Information
Table 60 : Bausch Health: Revenue, 2020-2022
Table 61 : Bayer AG: Product Information
Table 62 : Bayer AG: Financial Overview, 2020-2022
Table 63 : Bayer AG: Key Developments, 2022 and 2023
Table 64 : Biogen: Financial Overview, 2020-2022
Table 65 : Biogen: Key Developments, 2018-2023
Table 66 : Bristol-Myers Squibb: Product Information
Table 67 : Bristol-Myers Squibb: Financial Overview, 2020-2022
Table 68 : Bristol-Myers Squibb: Key Developments, 2021-2023
Table 69 : CSL: Product Information
Table 70 : CSL: Revenue, 2020-2022
Table 71 : CSL: Recent Developments, 2022
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Financial Overview, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Roche: Product Information
Table 76 : Roche: Revenue, 2020-2022
Table 77 : Roche: Key Developments, 2021-2023
Table 78 : Gilead Sciences: Financial Overview, 2020-2022
Table 79 : Gilead Sciences: Key Developments, 2022
Table 80 : GlaxoSmithKline plc: Product Segments
Table 81 : GlaxoSmithKline plc: Financial Overview, 2020-2022
Table 82 : GlaxoSmithKline plc: Recent Developments, 2022
Table 83 : Merck & Co. Inc.: Business Segments
Table 84 : Merck & Co. Inc.: Financial Overview, 2020-2022
Table 85 : Merck & Co. Inc.: Key Developments, 2022
Table 86 : Novartis: Product Information
Table 87 : Novartis: Financial Overview, 2020-2022
Table 88 : Novartis: Key Developments, 2023
Table 89 : Pfizer Inc: Product Segments
Table 90 : Pfizer Inc: Financial Overview, 2020-2022
Table 91 : Pfizer Inc: Top Brands, 2022
Table 92 : Pfizer Inc: Key Developments, 2019-2023
Table 93 : Sanofi: Business Segments
Table 94 : Sanofi: Annual Revenue, 2020-2022

Table 95 : Sanofi: Key Developments, 2021-2023

Table 96 : Servier: Annual Revenue, 2020-2022

Table 97 : Servier: Key Developments, 2022 and 2023

Table 98 : Teva: Financial Overview, 2020-2022

Table 99 : Teva: Key Developments, 2021-2023

Table 100 : Acronyms

List Of Figures

LIST OF FIGURES

Summary Figure A : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2020-2028

Summary Figure B : Global Market Shares of the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2022

Figure 1 : Global Factors Leading to the Prevalence of Myasthenia Gravis, by Region, 2022

Figure 2 : Global Market Shares of Myasthenia Gravis Treatments, by Region, 2022

Figure 3 : North American Market Shares of Myasthenia Gravis Treatments, by Country, 2022

Figure 4 : European Market Shares of Myasthenia Gravis Treatments, by Country, 2022

Figure 5 : Asia-Pacific Market Shares of Myasthenia Gravis Treatments, by Country, 2022

Figure 6 : Global Distribution of Types of Myasthenia Gravis, 2022

Figure 7 : Global Market Shares of Myasthenia Gravis Treatments, by Treatment Modality, 2022

Figure 8 : Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, Through 2022

Figure 9 : Global Electricity Production from Renewable Sources, 2017-2021

Figure 10 : Global Recycled Waste, 2017-2021

Figure 11 : Global CO₂ Emissions, 2017-2021

Figure 12 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022

Figure 13 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022

Figure 14 : AbbVie: Revenue Shares, by Country, 2022

Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022

Figure 16 : Daiichi Sankyo: Market Share, by Country/Region, 2022

Figure 17 : Gilead Sciences: Revenue, by Type of Product, 2022

Figure 18 : GlaxoSmithKline plc: Annual Revenue, by Segment, 2022

Figure 19 : Merck & Co. Inc.: Annual Revenue, Pharmaceutical Segment, 2022

Figure 20 : Novartis Innovative Medicines: Market Share, by Country/Region, 2022

Figure 21 : Novartis Sandoz: Market Share, by Country/Region 2022

Figure 22 : Sanofi: Revenue, by Region, 2022

Figure 23 : Sanofi: Revenue, by Segment, 2022

Figure 24 : Teva: Market Share, by Region, 2022

I would like to order

Product name: Global Myasthenia Gravis Treatment Market: Forecast and Trends

Product link: <https://marketpublishers.com/r/GF0CA1319AC3EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF0CA1319AC3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970